Skip to main content

Table 2 Information used to evaluate the proportion of patients achieving a response according to common criteria used in RA studiesa

From: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors

Measure

Number of biologics used

Number of patients

Estimated response rate, %

Specific biologics used to derive response rate

Treatment duration range, months

Mean age range, yr

Mean RA duration range, yr

Reference sources

ACR20

1

5,762

70.0

ADA

6 to 12

53 to 56

11 to 16

[30, 36, 51]

 

2

1,911

52.7

ADA, ETN, GLM, IFX, TCZ, TNF2

3 to 12

45 to 57

9 to 17

[14, 15, 17, 30, 32, 34, 36, 37, 51–53]

 

2+

772

53.3

ABA, RTX

6 to 12

52 to 53

12

[39, 41, 42]

 

3

339

40.6

ADA, GLM, TCZ, TNF3

3 to 6

51 to 58

11 to 15

[17, 32, 36, 52]

 

4

66

31.9

GLM, TCZ

4 to 6

51 to 54

11 to 13

[32, 52]

ACR50

1

5,736

41.1

ADA

3 to 12

54 to 56

11 to 16

[36, 51]

 

2

1,699

30.1

ETN, TCZ, TNF2, ADA, IFX

3 to 12

45 to 57

9 to 17

[14, 15, 17, 32, 34, 36, 37, 47, 51]

 

2+

1,078

23.5

GLM, ABA, RTX

4 to 12

52 to 55

9 to 12

[39, 41, 42, 52]

 

3

268

24.4

TCZ, TNF3, ADA

3 to 6

51 to 58

11 to 15

[17, 32, 36]

 

4

44

20.5

TCZ

6

51 to 54

11 to 13

[32]

ACR70

1

5,736

19.1

ADA

3 to 12

54 to 56

11 to 16

[36, 51]

 

2

1,686

12.0

ADA, ETN, TCZ, TNF2

3 to 12

49 to 57

8 to 17

[5, 17, 32, 34, 36, 37, 47, 51, 53]

 

2+

1,078

11.9

ABA, GLM, RTX

4 to 12

52 to 55

9 to 12

[39, 41, 42, 52]

 

3

268

12.7

ADA, TCZ, TNF3

3 to 6

51 to 58

11 to 15

[17, 32, 36]

 

4

44

4.5

TCZ

6

51 to 54

11 to 13

[32]

DAS28 <2.6

1

5,711

21.0

ADA

3

54

11

[36]

 

2

1,604

14.9

ABA, ADA, TNF2

3 to 6

53 to 56

12 to 14

[17, 29, 36]

 

2+

331

19.2

TCZ

6

51 to 54

11 to 13

[36]

 

3

496

10.2

ABA, ADA, TNF3

3 to 6

52 to 58

12 to 15

[17, 29, 36]

 

4

200

6.5

ABA

6

56

-

[29]

DAS28 <3.2

2

1,219

22.7

ABA,TNF2 TNTNF2

3 to 6

55 to 56

8 to 14

[17, 29, 40]

 

2+

331

33.7

TCZ

6

51 to 54

11 to 13

[32]

 

3

376

21.6

ABA TNF3

3 to 6

56 to 58

15

[17, 29]

 

4

200

15.0

ABA

6

56

-

[29]

EULAR moderate

1

6,494

48.0

ADA, TNF

3 to 8

54 to 57

8 to 11

[33, 36, 45]

 

2

1,854

44.4

ADA, ETN, TNF2

3 to 12

53 to 61

8 to 13

[35–38, 43, 45]

 

2+

324

49.7

TNF, RTX

6 to 9

52

12

[33, 39]

 

3

120

51.0

ADA

3

52

12

[36]

EULAR good

1

6,494

34.0

ADA, TNF

3 to 8

54 to 57

8 to 11

[33, 36, 45]

 

2

2,232

19.4

ADA, ETN, TNF2

3 to 12

53 to 61

8 to 14

[17, 36–38, 43–45, 53]

 

2+

324

15.3

TNF2+, RTX

6 to 9

52

12

[33, 45]

 

3

156

10.5

ADA, TNF3

3

52 to 58

12 to 15

[17, 36]

  1. aRA, rheumatoid arthritis; ACR, American College of Rheumatology; DAS28, Disease Activity Score 28 joint count; EULAR, European League Against Rheumatism. ABA, abatacept, ADA, adamlimumab, ANA, anakinra, ETN, etanercept, GLM, golimumab, IFX, infliximab, RTX, rituximab, TNFi, ith TNF-α inhibitor, TCZ, tocilizumab. ACR20 means a 20% improvement in tender or swollen joint counts as well as 20% improvement in at least three of the following five criteria: patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale and functional questionnaire. The ACR50 and ACR70 categories adhere to the same criteria, but for 50% and 70% improvement, respectively.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us